Abstract
Background
Docetaxel (DTX) is commonly used as a primary chemotherapy, and cabazitaxel (CBZ) has shown efficacy in patients who are DTX resistant. Primary prophylactic granulocyte colony stimulating factor (G-CSF) therapy is currently used with CBZ treatment in routine clinical care in Japan.
Methods
In this study, we performed a systematic review following the Minds guidelines to investigate the effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for prostate cancer and to construct G-CSF guidelines for primary prophylaxis use during chemotherapy. A comprehensive literature search of various electronic databases (PubMed, Cochrane Library, and Ichushi) was performed on January 10, 2020, to identify studies published between January 1990 and December 31, 2019 that investigate the impact of primary prophylaxis with G-CSF during CBZ administration on clinical outcomes.
Results
Ultimately, nine articles were included in the qualitative systematic review. Primary G-CSF prophylaxis during CBZ administration for metastatic castration-resistant prostate cancer was difficult to assess in terms of correlation with overall survival, mortality from infection, and patients’ quality of life. These difficulties were owing to the lack of randomized controlled trials comparing patients with and without primary prophylaxis of G-CSF during CBZ administration. However, some retrospective studies have suggested that it may reduce the incidence of febrile neutropenia.
Conclusion
G-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a “weak recommendation to perform” with an annotation of the relevant regimen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512
Naito S, Tsukamoto T, Koga H et al (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol 38(5):365–372
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154. https://doi.org/10.1016/S0140-6736(10)61389-X
Nozawa M, Mukai H, Takahashi S et al (2015) Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol 20(5):1026–1034. https://doi.org/10.1007/s10147-015-0820-9
https://www.pmda.go.jp/files/000143619.pdf. Accessed 22 Nov 2023
de Wit R, de Bono J, Sternberg CN et al (2019) Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 381(26):2506–2518. https://doi.org/10.1056/NEJMoa1911206
Kakehi Y, Sugimoto M, Taoka R (2017) Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int J Urol 24(9):648–666
Meisel A, von Felten S, Vogt DR et al (2016) Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial. Eur J Cancer 56:93–100. https://doi.org/10.1016/j.ejca.2015.12.009
Suzuki K, Matsubara N, Kazama H et al (2019) Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study. Jpn J Clin Oncol 49(12):1157–1163. https://doi.org/10.1093/jjco/hyz108
Di Lorenzo G, D’Aniello C, Buonerba C et al (2013) Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs 24(1):84–89. https://doi.org/10.1097/CAD.0b013e32835a56bc
Kosaka T, Uemura H, Sumitomo M et al (2019) Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan. Jpn J Clin Oncol 49(8):766–771. https://doi.org/10.1093/jjco/hyz051
Bahl A, Masson S, Malik Z et al (2015) Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK early access programme (EAP) (NCT01254279). BJU Int 116(6):880–887. https://doi.org/10.1111/bju.13069
Azuma K, Kawakami K, Yuasa K et al (2018) Safety of pegfilgrastim as primary prophylaxis for cabazitaxel treatment. Jpn J Cancer Chemother 45:1737–1742
Heidenreich A, Bracarda S, Mason M et al (2014) Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer 50(6):1090–1099. https://doi.org/10.1016/j.ejca.2014.01.006
Koutake Y, Takatake Y, Fujita T et al (2019) Efficacy of pegfilgrastim as primary prophylaxis for castration-resistant prostate cancer treated with docetaxel. Jpn J Cancer Chemother 46:1721–1725
Acknowledgements
The authors thank Dr. Toshimi Takano and Ms. Natsuki Fukuda for their valuable comments and suggestions.
Funding
The present study did not receive any funding.
Author information
Authors and Affiliations
Contributions
All authors contributed to the conception and design of the study. The first draft of the manuscript was written by S.K., and all authors commented on the previous version of the manuscript. All authors have read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
No author has any conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kimura, S., Shigeta, K., Tamura, S. et al. Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022. Int J Clin Oncol 29, 559–563 (2024). https://doi.org/10.1007/s10147-024-02501-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-024-02501-7